FR17C1020I2 - Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6 - Google Patents

Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Info

Publication number
FR17C1020I2
FR17C1020I2 FR17C1020C FR17C1020C FR17C1020I2 FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2 FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2
Authority
FR
France
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1020C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of FR17C1020I1 publication Critical patent/FR17C1020I1/fr
Publication of FR17C1020I2 publication Critical patent/FR17C1020I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR17C1020C 2008-04-16 2017-06-06 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6 Active FR17C1020I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (2)

Publication Number Publication Date
FR17C1020I1 FR17C1020I1 (sl) 2020-04-10
FR17C1020I2 true FR17C1020I2 (fr) 2020-04-10

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1020C Active FR17C1020I2 (fr) 2008-04-16 2017-06-06 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Country Status (29)

Country Link
US (6) US8951967B2 (sl)
EP (7) EP2808340B1 (sl)
JP (7) JP2011519359A (sl)
KR (5) KR20180095140A (sl)
CN (3) CN105906703A (sl)
AR (1) AR071479A1 (sl)
AU (5) AU2009237479B2 (sl)
BR (1) BRPI0910461B8 (sl)
CA (1) CA2725257A1 (sl)
CY (1) CY1115413T1 (sl)
DK (4) DK3045471T3 (sl)
ES (3) ES2468318T3 (sl)
FR (1) FR17C1020I2 (sl)
HK (2) HK1146284A1 (sl)
HR (3) HRP20140535T1 (sl)
HU (5) HUE033830T2 (sl)
IL (2) IL208538A (sl)
LT (5) LT3098234T (sl)
MX (3) MX2010011343A (sl)
NO (2) NO2017025I1 (sl)
NZ (1) NZ588381A (sl)
PL (4) PL3144318T3 (sl)
PT (4) PT2808340T (sl)
RU (3) RU2682270C2 (sl)
SA (1) SA109300228B1 (sl)
SI (4) SI3144318T1 (sl)
TW (1) TWI488640B (sl)
WO (1) WO2009127826A1 (sl)
ZA (1) ZA201007373B (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
US20130224797A1 (en) 2010-10-15 2013-08-29 Jcr Pharmaceuticals Co., Ltd. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
DK3283097T3 (da) 2015-04-17 2020-04-20 Ferring Bv Fsh til behandling af infertilitet
WO2016207353A1 (en) 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
JOP20200034A1 (ar) 2017-09-01 2020-02-13 Ferring Bv تركيبة للتنشيط المتحكم فيه للمبيض
JP2021522268A (ja) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
CN1608078B (zh) * 2001-10-22 2012-07-25 默克雪兰诺有限公司 用于卵泡生成的促性腺激素
DK1440157T3 (da) 2001-10-29 2012-05-07 Crucell Holland Bv Methods and means for producing proteins with predetermined post-translational modifications
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
CA2554968C (en) 2004-02-04 2012-03-27 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
EP2600809B1 (en) 2010-08-03 2015-02-25 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
EP2691119B1 (en) 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
EP3045471A1 (en) 2016-07-20
HK1146284A1 (en) 2011-05-20
PL2808340T3 (pl) 2017-02-28
US11952407B2 (en) 2024-04-09
LT3098234T (lt) 2024-09-10
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
DK2808340T3 (en) 2016-12-05
JP2024038000A (ja) 2024-03-19
EP3098234B1 (en) 2024-07-31
AU2014203277B2 (en) 2017-04-06
BRPI0910461A8 (pt) 2018-10-16
SI3045471T1 (sl) 2017-07-31
HUS1700025I1 (hu) 2017-06-28
RU2010141908A (ru) 2012-05-27
US20180079794A1 (en) 2018-03-22
ZA201007373B (en) 2011-06-29
HRP20170958T1 (hr) 2017-09-22
ES2468318T3 (es) 2014-06-16
SI3144318T1 (sl) 2020-12-31
EP3045471B1 (en) 2017-03-29
EP2268666B1 (en) 2014-03-12
HUS1700036I1 (hu) 2017-10-30
CA2725257A1 (en) 2009-10-22
JP7316905B2 (ja) 2023-07-28
BRPI0910461A2 (pt) 2018-03-27
AU2014203277A1 (en) 2014-07-24
US20240327487A1 (en) 2024-10-03
NO2017050I1 (no) 2017-09-28
AU2017204259A1 (en) 2017-07-20
JP2011519359A (ja) 2011-07-07
RU2014141994A3 (sl) 2018-05-28
JP6762916B2 (ja) 2020-09-30
AU2014203277C1 (en) 2017-07-27
SI2808340T1 (sl) 2016-12-30
AR071479A1 (es) 2010-06-23
JP2022031652A (ja) 2022-02-22
US20160347811A1 (en) 2016-12-01
KR20190092608A (ko) 2019-08-07
BRPI0910461B8 (pt) 2021-05-25
AU2017225020B2 (en) 2019-11-14
PT3045471T (pt) 2017-06-14
KR20170110741A (ko) 2017-10-11
PL3144318T3 (pl) 2021-02-08
US10995128B2 (en) 2021-05-04
EP2808340A1 (en) 2014-12-03
KR20160056960A (ko) 2016-05-20
KR20110005863A (ko) 2011-01-19
DK3045471T3 (en) 2017-06-26
US9771407B2 (en) 2017-09-26
HRP20161520T1 (hr) 2016-12-30
EP3144318A1 (en) 2017-03-22
KR101622944B1 (ko) 2016-05-23
RU2745557C1 (ru) 2021-03-29
AU2009237479B2 (en) 2014-05-15
JP2020040956A (ja) 2020-03-19
DK2268666T3 (da) 2014-05-12
FR17C1020I1 (sl) 2020-04-10
HUE033830T2 (en) 2018-01-29
HK1199039A1 (en) 2015-06-19
CN102066414A (zh) 2011-05-18
EP4015527A1 (en) 2022-06-22
LT3045471T (lt) 2017-07-10
PL2268666T3 (pl) 2014-08-29
SA109300228B1 (ar) 2014-04-08
PT3144318T (pt) 2020-11-04
US20210332099A1 (en) 2021-10-28
ES2629392T3 (es) 2017-08-09
WO2009127826A1 (en) 2009-10-22
DK3144318T3 (da) 2020-12-07
EP3098234A1 (en) 2016-11-30
LTPA2017018I1 (lt) 2017-06-26
JP6486310B2 (ja) 2019-03-20
RU2682270C2 (ru) 2019-03-18
CY1115413T1 (el) 2017-01-04
HUE030652T4 (en) 2017-09-28
JP2015120696A (ja) 2015-07-02
RU2014141994A (ru) 2016-05-10
MX348622B (es) 2017-06-22
US20150065695A1 (en) 2015-03-05
IL208538A (en) 2014-03-31
US9546204B2 (en) 2017-01-17
PT2808340T (pt) 2016-11-21
US20110105398A1 (en) 2011-05-05
KR102108377B1 (ko) 2020-05-08
IL230571A (en) 2015-11-30
HUS1700024I1 (hu) 2017-06-28
SI2268666T1 (sl) 2014-07-31
PT2268666E (pt) 2014-06-25
RU2745557C3 (ru) 2021-12-10
AU2017204258A1 (en) 2017-07-20
CN105906703A (zh) 2016-08-31
AU2009237479A1 (en) 2009-10-22
AU2017204259B2 (en) 2017-08-17
AU2017225020A1 (en) 2017-09-28
JP2018021037A (ja) 2018-02-08
BRPI0910461B1 (pt) 2021-02-23
PL3045471T3 (pl) 2017-10-31
TWI488640B (zh) 2015-06-21
CN105906702A (zh) 2016-08-31
EP2808340B1 (en) 2016-08-17
JP2017060476A (ja) 2017-03-30
LT2808340T (lt) 2016-11-10
IL208538A0 (en) 2010-12-30
EP2722339A1 (en) 2014-04-23
HUE030652T2 (en) 2017-05-29
US8951967B2 (en) 2015-02-10
RU2537268C2 (ru) 2014-12-27
EP2268666A1 (en) 2011-01-05
NO2017025I1 (no) 2017-06-06
NZ588381A (en) 2012-05-25
LTPA2017029I1 (lt) 2017-10-10
EP3144318B1 (en) 2020-09-23
MX355457B (es) 2018-04-19
AU2017204258B2 (en) 2017-08-17
TW200948378A (en) 2009-12-01
MX2010011343A (es) 2011-01-20
KR20180095140A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
FR17C1020I2 (fr) Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
BRPI0917120A2 (pt) método, e, meio legível por computador.
ITVE20060045A1 (it) Dispositivo riscaldatore per calzature, guanti e simili.
BRPI0815773A2 (pt) composto, e, medicamento.
BRPI0919412A8 (pt) composição imunonutricional e nutricional,agente intensificador de resposta imunológica e uso do mesmo.
Meroni et al. CRAWDAD dataset unimi/pmtr (v. 2008-12-01)
JP2012513655A5 (sl)
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
BRPI0919168A2 (pt) pestivírus mutante, e, vacina.
Eser Palleh Hyongbop Chongnon, Bulpopgwa Choungdanghwae Gwanhan Ilbanwonchik
HUE051918T2 (hu) Alfa 2,3- és alfa 2,6-szialilációt tartalmazó rekombináns FSH
TH103053B (th) ระบบแฟรนไชส์แอดออนกับเทอร์มินัลปฏิบัติการของผู้บริโรคกับชั้นสต็อกหน้าร้านและชั้นสต๊อกสำรองนั้น
TH71292B (th) โคพอลิเมอร์ของโพรพิลีน-อัลฟา-โอเลฟินชนิดกิ่งก้านสายโซ่ยาว
CN301071626S (zh) 客车(eq6750p3g)
TH113134S (th) เก้าอี้สำหรับใช้ประกอบส้วม
TH111363S (th) เก้าอี้
TH106419S (th) เก้าอี้
TH111364S (th) เก้าอี้
TH111365S (th) เก้าอี้
TH111883S (th) เก้าอี้
TH106414S (th) เก้าอี้
TH106413S (th) เก้าอี้
TH106412S (th) เก้าอี้
SE0801220L (sv) Hurry 1.3
IT1396447B1 (it) Dispositivo per la cottura in forno di arrosticini, spiedini e simili.